Pindolol: experience gained in 10 years of safety monitoring.

The benefit to be expected from any drug therapy should outweigh its inherent risk. All adverse events reported in connection with administration of pindolol have been carefully analyzed since this drug was marketed 10 years ago. The investigation included the data published in the literature, the information provided by spontaneous reporting or by bulletins issued by various national drug evaluation committees, and the results obtained by intensive hospital monitoring.

Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs.

The antihypertensive effect of pindolol has been demonstrated in several hundred clinical trials performed in many countries. The results of several representative trials will be reviewed in this article. In a cooperative study of pindolol by Swiss internists, blood pressure (BP) normalization was achieved in 76% of the patients and a fair response in 9%.